MetLife Investment Management LLC Acquires 5,115 Shares of ChromaDex Co. (NASDAQ:CDXC)

MetLife Investment Management LLC boosted its holdings in ChromaDex Co. (NASDAQ:CDXC) by 39.3% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 18,114 shares of the company’s stock after acquiring an additional 5,115 shares during the quarter. MetLife Investment Management LLC’s holdings in ChromaDex were worth $66,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in CDXC. Renaissance Technologies LLC raised its stake in ChromaDex by 8.4% during the 2nd quarter. Renaissance Technologies LLC now owns 416,100 shares of the company’s stock valued at $1,136,000 after buying an additional 32,400 shares during the last quarter. WINTON GROUP Ltd purchased a new stake in ChromaDex during the 2nd quarter valued at $597,000. Bank of New York Mellon Corp raised its stake in ChromaDex by 170.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 190,442 shares of the company’s stock valued at $520,000 after buying an additional 119,915 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its stake in ChromaDex by 10.8% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 175,172 shares of the company’s stock valued at $639,000 after buying an additional 17,115 shares during the last quarter. Finally, BSW Wealth Partners purchased a new stake in ChromaDex during the 3rd quarter valued at $324,000. 15.41% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on CDXC shares. Roth Mkm boosted their target price on shares of ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a research note on Wednesday, November 6th. HC Wainwright boosted their target price on shares of ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a research note on Monday, November 4th. Finally, StockNews.com upgraded ChromaDex from a “buy” rating to a “strong-buy” rating in a research note on Monday.

ChromaDex Price Performance

NASDAQ:CDXC opened at $6.71 on Wednesday. The firm has a market capitalization of $512.51 million, a price-to-earnings ratio of 671.67 and a beta of 2.15. ChromaDex Co. has a one year low of $1.32 and a one year high of $7.97. The business has a fifty day moving average price of $5.48 and a 200-day moving average price of $3.92.

ChromaDex (NASDAQ:CDXC) last posted its quarterly earnings data on Thursday, October 31st. The company reported $0.02 EPS for the quarter. The firm had revenue of $25.58 million during the quarter, compared to analyst estimates of $23.70 million. ChromaDex had a return on equity of 4.85% and a net margin of 1.62%. During the same period in the prior year, the business posted ($0.01) EPS. On average, equities research analysts expect that ChromaDex Co. will post 0.04 earnings per share for the current fiscal year.

ChromaDex Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.